A New View of the Spectrum of HER2 Expression and Significance of HER2 Low in Breast Cancer

A New View of the Spectrum of HER2 Expression and Significance of HER2 Low in Breast Cancer
Co-Chairs, Stuart J. Schnitt, MD, and Paolo Tarantino, MD, and Jorge S. Reis-Filho, MD, PhD, FRCPath, discuss breast cancer in this CME/MOC/CC activity titled “A New View of the Spectrum of HER2 Expression and Significance of HER2 Low in Breast Cancer: Exploring the Biology and Updating Best Practices for Testing and Treatment.” For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC information, and to apply for credit, please visit us at PeerView.com/NRG865. CME/MOC/CC credit will be available until April 12, 2024.